|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Departments of Immunology, Hematology and
Internal Medicine, and Surgery, Mayo Clinic, Rochester, MN.
Multiple myeloma (MM) is a plasma cell disorder that potentially
initiates during an early stage of B-cell development. We encountered
an unidentified isoform of B cell-specific activator protein
(BSAP, or Pax5) in MM cells while performing differential analyses to
compare mRNA expression in malignant and normal plasma cells. Pax5 is a
transcription factor that plays a central role throughout B-cell
development until the point of terminal differentiation. Our finding of
this unique isoform prompted us to investigate Pax5 isoform usage in
plasma cells and B-cell populations in other MM and healthy
subjects. In contrast to normal Pax5 expression, we observed multiple
isoforms of Pax5 in conjunction with low levels of expression of the
full-length Pax5 in B cells from MM patients. The expressed isoforms in
MM varied considerably from patient to patient, with no clear pattern.
We also performed semiquantitative analyses of the mRNA expression
levels of B lymphocyte-induced maturation protein (Blimp-1),
because expression levels of Pax5 and Blimp-1 have been shown to be
inversely correlated. We observed the expression of Blimp-1 in the
B-cell populations in all 11 MM patients but in none of 11 healthy
subjects. We hypothesize that premature Blimp-1 expression coupled to
altered and deficient Pax5 expression causes some proliferating B cells
to prematurely differentiate to plasma cells in MM.
(Blood. 2002;100:4629-4639) Multiple myeloma (MM) is a monoclonal neoplasm of
mature immunoglobulin-secreting plasma cells. It is unknown if the
neoplasm first develops within mature plasma cells or if dysregulation occurs in the molecular pathway(s) leading to the development of mature
plasma cells. Treatments have included immunotherapy with
tumor-specific peptides that are not expressed by normal, healthy
cells. Tumor vaccines, including dendritic cell-based vaccinations
with idiotype, have shown promise as treatment.1,2 The
monoclonal protein, as a source of tumor-specific peptides, is an
obvious target for tumor vaccines, but concerns have been raised about
the utility of the idiotype as a potential target.3,4 A
number of investigators have confirmed the existence of
idiotype-specific T cells in mouse plasmacytoma models5,6
and in in vitro studies of human peripheral blood lymphocytes
(PBLs).7,8 Yet, for unknown reasons, these
idiotype-specific T cells do not function effectively in
vivo.9,10 Thus, the need exists to identify and test
alternative tumor-specific peptides as potential targets for immunotherapy.
A search for new MM-specific peptides could conceivably be expedited if
a clear understanding of the pathway(s) involved in the transcriptional
control of MM were known. Unfortunately, such knowledge for MM remains
elusive. Multiple aberrant mRNA expression levels have been detected in
studies of gene expression in MM, but it has been difficult to
associate these findings with a common point of origin or with common
pathways. Data obtained from differential analyses with the use of
microarrays will contribute significantly to our ability to identify
pathways and define the course of development of MM. However,
microarrays are deterministically arranged and are considerably less
useful when the need arises to detect previously unidentified mRNA
transcripts. It is also important to be able to identify, characterize,
and estimate the expression levels of alternatively spliced isoforms. A
means to identify alternatively spliced transcripts is particularly
important when attempting to characterize gene expression in
proliferating and differentiating cells, because alternative splicing
can provide the economical use of a single gene to rapidly perform
multiple tasks.
We performed differential analyses to search for novel genes that could
provide MM-specific peptides for use as cytotoxic T-lymphocyte
(CTL) determinants. We used a technique known as RNA fingerprinting by
arbitrarily primed polymerase chain reaction (RAP-PCR) to
compare in vivo gene expression profiles in B-cell and plasma cell
populations from MM patients versus healthy individuals. RAP-PCR takes
advantage of primer sequences (10 bases) that occur at approximately
500-base pair increments in genomic DNA.11 First-strand
cDNA syntheses that are primed with either an arbitrary primer or an
oligo(dT) primer serve as templates in PCRs where the upstream primers
are also arbitrary primers. RAP-PCR can be performed with picograms of
mRNA, thus avoiding the need to supply the larger amounts of RNA
required for chip arrays. Theoretically, with sufficient primer
combinations, reverse transcriptase-PCR (RT-PCR) products will be
generated for most mRNA transcripts. Thus, this technique can provide
information on novel gene expression, alternatively spliced
transcripts, and induced and suppressed expression of mRNAs.
We encountered an unusual, alternatively spliced isoform of the B
cell-specific activator protein (BSAP, or Pax5) in plasma cells from
an MM patient in a differential analysis experiment. Pax5 is a
transcription factor that contributes significantly to the process of
B-cell development and differentiation that culminates in the
production of fully differentiated plasma cells.12 In
Pax5 Isolation of cells
Messenger RNA extraction
Primer synthesis Primers were synthesized by Mayo Molecular Biology Core (Mayo Clinic, Rochester, MN) with retention of the 5'-protecting group (dimethoxytrityl; PE Applied Biosystems, Foster City, CA).RNA fingerprinting by arbitrarily primed PCR RAP-PCR methodology was adapted to one-tube, hot-started RT-PCRs.11,19-21 Two cDNA synthesis master mixes were prepared for 24 20-µL reactions. Reaction concentrations were 10 mM Tris (tris(hydroxymethyl)aminomethane) HCl (pH 8.3), 50 mM KCl, 5 mM MgCl2, and 0.25 mM each deoxyribonucleoside triphosphate (dNTP) (Promega, Madison, WI). Each reaction received 20 pmol of arbitrary primer AP-21,20 0.5 units of PRIME RNase INHIBITOR (5' 3'), 4 units of Moloney murine leukemia virus reverse transcriptase (M-MLV RT; Life Technologies, Gaithersburg, MD)
and 400 pg mRNA. Messenger RNAs from normal and malignant plasma cells
were added to separate mixes. The mRNAs were denatured at 70°C for 3 minutes. Each cDNA synthesis mixture was aliquotted into 24 0.5-mL
tubes, and cDNA was synthesized on a 380 DNA Thermal Cycler (PE Applied
Biosystems) with a 7-minute ramp from room temperature to 37°C, 15 minutes of incubation at 37°C, followed by 20 minutes at 42°C.
Following cDNA synthesis, provision for a subsequent hot-start PCR was
made by addition of an AmpliWax PCR Gem 100 Pellet (PE Applied
Biosystems) to each tube before incubation at 100°C for 5 minutes to
inactivate M-MLV RT. For the PCR layer, 24 mixes were prepared, with
each receiving 1 of a set of 24 arbitrary primers (AP1-AP20 and
AP22-AP25) for use with a normal/malignant template pair following the
first-strand cDNA synthesis.20 This layer had a final
volume of 80 µL and consisted of 1.25 mM MgCl2, 10 mM
Tris-HCl (pH 8.3), 50 mM KCl, 20 pmol of 1 arbitrary primer, and 1.25 units of Taq DNA Polymerase (Promega). Cycling parameters were (1) 1 cycle with 94°C for 5 minutes, 25°C for 30 seconds, a ramp of 5 minutes to 72°C, and 72°C for 2 minutes; (2) 40 cycles with 94°C
for 1 minute, 40°C for 30 seconds, and 72°C for 1 minute; and (3) 1 cycle with 7 minutes at 72°C.
Product selection, reamplification, and identification RAP-PCR products were separated by agarose gel electrophoresis and reamplifed in standard PCRs with the respective primer pair using the cycling parameters as described above for the PCR stage of the RT-PCR. The reamplification products were sequenced by the Mayo Molecular Biology Core with the respective AP primers on a Model 373A Automated Sequencer (PE Applied Biosystems). Acquired sequence data were analyzed on the National Center for Biotechnology Information basic local alignment search tool (NCBI BLAST) server.22Gene-specific RT-PCRs for full-length Pax5 Full-length Pax5 products were generated with the use of a Qiagen OneStep RT-PCR Kit (Qiagen). Cycling parameters for the cDNA synthesis were 50°C for 32 minutes followed by 95°C for 15 minutes, and the PCR was performed with 40 cycles of 1 minute at 94°C, 30 seconds at 55°C, and 1 minute 30 seconds at 72°C with a final incubation at 72°C for 10 minutes. Pax5 primers E1-F and E10-R were used (Table 1), and cycling was performed in a DNA Engine Tetrad (MJ Research, Waltham, MA).
Gene-specific RT-PCRs for all other gene products These RT-PCRs were one-tube, hot-started reactions as described above for RAP-PCR. First-strand cDNA synthesis was primed with 20 pmol of gene-specific reverse primers, and 20 pmol of upstream gene-specific primers were added at the PCR stage. For semiquantitative analyses, starting mRNA templates were 350 pg of mRNA. Cycling parameters were (1) 1 cycle with 94°C for 5 minutes, 55°C for 30 seconds, and 72°C for 2 minutes; and (2) 35 cycles with 94°C for 1 minute, 56°C for 30 seconds, and 72°C for 1 minute, with a final incubation at 72°C for 7 minutes. All reactions were normalized to -actin expression. Primer pairs used to generate 585 and 754 bp
products at the 3'-end of the coding region of Pax5 (Table 1) were
E5/6-F paired with E10-R and E4-F paired with E10-R, respectively.
BLIMP-1 primers were ACACACGGGAGAAAAGCCAC and CTTGTGGCACTGGGAGCAC; A1
primers were GTCCTACAGATACACAACC and TCCTTATAGGTATCCACATCC. The
-actin primers were CATTGGCAATGAGCGGTTGG and AGTGATCTCCTTCTGCATCC.
Primers used to generate products for the alternative 3'-end product of
Pax5 were E3-F (Table 1) and downstream primer GGACTCGCTCCTCTGCAGG
(located in the intron between exons 5 and 6).
Nested PCRs for analysis of exon 2+ RT-PCR Pax5 products We performed nested PCRs using full-length Pax5 transcripts as template to determine the composition of some Pax5 products. A total of 8 forward and 8 reverse primers based on sequence from each exon 1-8 and each exon 3-10, respectively, were synthesized for the purpose of "spanning" the entire Pax5 transcript in overlapping fragments by PCR (Table 1). PCR cycling parameters were the same as for gene-specific RT-PCRs but with 25 cycles.Genomic analysis Human genome databases were accessed through NCBI,22 GCG (Wisconsin Package Version 10.2, Genetics Computer Group, Madison, WI), and the Celera Discovery System, Celera, Rockville, MD.
Clinical status of patients at the time of BM harvests Plasma cell percentages (BM%), plasma cell labeling indexes (PCLIs), types of treatment if any, patient status at sample time, and other comments on patient status are shown in Table 2. Treated patients, with the exception of P18, included those who had received some form of chemotherapy prior to the time of the BM harvest. P18 had been treated with dexamethasone and radiation to a spine plasmacytoma. BM samples from untreated MM patients were harvested at diagnosis.
Detection of a Pax5 isoform in a RAP-PCR differential analysis As a means of identifying aberrant gene expressions in plasma cells of MM patients, we used RAP-PCR differential analyses to compare the gene expression profiles in plasma cells of MM patients and healthy individuals. Messenger RNAs were used as templates. A RAP-PCR using cDNA synthesis primer AP-21 and forward primer AP-14 generated a product of 180 bp that was observed exclusively in the plasma cell sample from MM patient P1. The product was identified by sequence analysis as a unique isoform of Pax5 from which exons 2, 3, and 4 had been deleted but which stayed in frame for Pax5 protein sequence downstream of the deletion (Figure 1). This patient appeared to be heterozygous with both the reported G and an alternative A at the15th nucleotide position upstream of the deletion. The Pax5 polypeptide is a typical transcription factor and is composed of a paired DNA-binding domain, an octapeptide region, a short region of homeodomain homology, and a transactivating region (Figure 2A).23 The deletion of exons 2, 3, and 4 would remove the entire paired domain region of Pax5.
RT-PCR products of 3'-ends of the coding regions of Pax5 isoforms The finding of a previously unidentified isoform for Pax5 prompted us to investigate Pax5 isoform usage in other MM patients and healthy subjects. The full-length Pax5 transcript has been identified in human cell lines and B lymphocytes, but an isoform from which exon 2 has been deleted, as observed in mouse studies, has not been well characterized in human studies.24-26We used mRNA templates from B cell-enriched populations for these
RT-PCRs because Pax5 expression would expectedly be low or absent in
normal plasma cells. Shown in Figure 3
are RT-PCR products that were generated with a pair of primers designed
to amplify an expected 585-bp product in the 3'-end of the coding region of Pax5 including exons 6 to 10. The expected 585-bp product was
observed in mRNAs from both healthy donors but in neither of the mRNAs
from MM patients. Both normal samples have the same basic pattern of
expression, albeit with potentially different levels of expression of
individual products. None of the products of 300 bp or less were
readily identifiable; thus, a 3'-end Pax5 product was not identified
for sample P8. The largest product detected for P3 was subsequently
shown to consist of 2 products of sizes 498 bp and 483 bp (Figure 3,
arrow). Sequencing of these products revealed that the 498 bp product
was missing exon 9, and the 483 bp product was missing exon 8. Both of
these isoforms stayed in frame for Pax5 translation following the
deletions. A product observed at 396 bp in P3, H3, and H1 is
an isoform missing both exons 7 and 8, and it appears to be more
strongly expressed in sample H1 than the expected 585-bp product. These
isoforms encode for an additional unique stretch of 64 amino acids. An unusual product detected in both normal samples at 500 bp was determined to be a hybrid mix composed of one strand of the expected 585-bp Pax5 and one strand of the isoform missing exons 7 and 8.
We performed a similar experiment with 6 more MM patients and 3 healthy
subjects using a pair of primers designed to amplify an expected 754-bp
product in the 3'-end of the coding region of Pax5, including exons 4 to 10 (Figure 4A). The expected 754-bp product was observed in mRNAs from all 3 healthy donors, but only traces of expression were observed in mRNAs from untreated MM patients.
The expected product was observed in 2 of 3 treated patients but only
faintly in one of these. All other products generated with this primer
set were determined to be nonspecific upon sequencing.
RT-PCR search for a Pax isoform with replacement of exons 6 to 10 as observed in mouse (isoforms Pax5d and 5e) Two additional mouse Pax5 isoforms, with (Pax5d) and without exon 2 (Pax5e), have replaced exons 6 to 10 with 129 bases of novel sequence.13 Human versions of these isoforms have not been reported. We considered that if this isoform were expressed in human B cells, it is perhaps predominant in MM patients and replaces the normal 3'-end. We aligned the sequence data from the mouse 3' alternative-end to genomic data in the Celera database and determined that the alternative sequence observed in mice lay within the intron immediately distal to exon 5. We then used gene-specific primers in RT-PCRs to generate a product that spanned 2 introns, which ruled out generation of a product from genomic DNA (Figure 4B). All B-cell populations from MM patients and healthy subjects strongly expressed this alternative Pax5 isoform. The stretch of nucleotides replacing exons 6 to 10 in humans is 45 bases longer than that in mice and confirmed to come from the intron region homologous to mouse (Figure 5).
Pax5 isoform profiles differ in healthy subjects, untreated MM patients, and treated MM patients The findings of exon deletions near the 3'-end of Pax5 were potentially unimportant because an isoform of Pax5 that is missing exon 2 is likely normally expressed at the time of terminal differentiation, and the loss of exon 2 causes a frame shift that results in an abortion of translation 12 amino acids downstream of the deletion.13 Thus, we designed primers in the 5'-UTR (untranslated region) of Pax5 and near the 3'-end of exon 10 to use in RT-PCRs to generate and identify those products that retained exon 2. If a full-length product could not be sequenced due to cross-hybridization among alternative isoforms, a series of overlapping PCR nests were performed using the full-length product as template to determine the composition of the hybrid products.Compiled in Figure 6A are the results of
these RT-PCRs and nested PCRs for B cells and plasma cells,
respectively. The isoform that is missing exons 7 and 8 in tandem is
consistently expressed in normal B cells, while B cells from only 33%
of untreated MM patients expressed this isoform. The incidence of the
7-8 (
We also sought to enhance the purity of the B cell-enriched
populations by extracting CD22+ cells from the
CD138 We attempted to semiquantitate the full-length Pax5 transcripts because it is commonly more difficult to generate this product in MM patients than in healthy subjects. The semiquantitative results are potentially misleading, however, because these products were invariably cross-hybridized with other isoforms. Thus, any of the patients that show strong full-length Pax5 products may actually be expressing only low levels of full-length product. Schematic illustrations of the isoforms missing exons 8, 9, 7-8 in tandem, 7-9 in tandem, and the isoform with an insert between exons 8 and 9 Shown in Figure 7 are the sequences of the predominant Pax5 isoforms with changes in the 3'-end of Pax5. Isoforms with either exon 8 or exon 9 deletions stay in frame for Pax5 following the deletion. One of the MM patients with an exon 8 deletion exhibited a single, nonsynonymous base change (ThrAla) at the 16th
nucleotide prior to the splice site. The putative protein sequence
downstream of the deletion in the isoforms missing exons 7-8 and exons
7-9 code for out-of-frame Pax5 stretches of 64 and 35 amino acids, respectively. The isoform with an insert between exons 8 and 9 translates as Pax5 up through exon 8 and then codes for 62 additional amino acids of non-Pax5 sequence. The insert is a portion of the KIAA0040 gene, at chromosomal position 1q23, first identified in the
immature myeloid cell line KG-1.27 This gene has a coding region of 154 amino acids with no known function.
Possible correlations between clinical data and Pax5 isoform profiles The 2 patients with the highest PCLIs, P17 and P13, are also those who are likely to have the most severely compromised Pax5 function (Table 1 and Figure 6). P17 carries the Pax5 insert between exons 8 and 9 in the plasma cells and has 5 identified isoforms in B cells. A full-length Pax5 transcript wax not detected for P13. The patient with relapsing MM (P3) and one of the patients with no response to treatment (P11) have the highest number of Pax5 isoforms in the B cells; a patient who shows no response to treatment is a patient with smoldering multiple myeloma (P12) and has a relatively normal Pax5 profile. It may be of interest that other tissues that express Pax5 are the developing hindbrain, kidney, genital tract, and thyroid.28,29 Two patients have neuropathy (P7 and P12), one has renal failure (P13), one has an enlarged prostate gland (P17), and one has gout (P6).Blimp-1 expression in B cells and plasma cells from healthy subjects and MM patients One means of investigating Pax5 function where unique isoforms were observed was to investigate the expression of B lymphocyte-induced maturation protein (Blimp-1). Blimp-1 is also a critical transcription factor in B-cell development because it is both required and sufficient to trigger terminal differentiation of B cells to immunoglobulin (Ig)-secreting plasma cells.17,18 It has been observed that a low Pax5 phenotype is always associated with increased Blimp-1 expression, although the reason for the inverse correlation is not yet clear.14,16 However, it would be expected that under normal conditions Blimp-1 expression would be down-regulated in the B-cell population and up-regulated in plasma cells in an inverse relationship to Pax5 expression levels.We performed semiquantitative RT-PCRs to investigate Blimp-1
expression in plasma cells and B cell-enriched populations from MM
patients and healthy subjects. Shown in Figure
8 are the results of one of the Blimp-1
RT-PCRs. In this experiment, the B-cell populations of 3 MM patients
were positive for Blimp-1 expression, while both of the normal B-cell
populations were negative. The available plasma cell populations from
these same 5 individuals were all positive for Blimp-1 expression. An
apparent greater level of expression was observed in the malignant
plasma cells than in the normal plasma cells. A summary of all the
Blimp-1 RT-PCR results is shown in Table
3. We observed Blimp-1 expression in all
7 B cell-enriched populations from MM patients that were analyzed. In
contrast, we did not observe Blimp-1 expression in any of 11 B-cell
populations from healthy subjects.
Blimp-1 expression in CD22+ and CD22 -actin in both the
CD22+ and CD22 B-cell populations by RT-PCR
(Figure 9). Three of 4 of the
CD22+ populations and all of the CD22
populations were positive for Blimp-1 expression (Figure 9B). An
inverse correlation between full-length Pax5 (Figure 9A) and Blimp-1
(Figure 9B) levels of expression was observed in all samples with the
exception of the CD22+ cells from P15.
A1 expression in B cells and plasma cells from healthy subjects and MM patients It has been shown that overexpression of Blimp-1 results in a down-regulation of the A1 antiapoptotic bcl-2 family member in murine WEHI 231 cells.30 It follows that if Blimp-1 were prematurely expressed in a B-cell population, A1 expression could be repressed. We investigated A1 expression in B cell-enriched populations from MM patients and healthy subjects by semiquantitative RT-PCR (Figure 10A). In agreement with early expression of Blimp-1 in the MM B-cell populations, we did not observe expression of A1 in any of these samples. We did, however, observe a low level of A1 expression in the normal samples. The negative results obtained for malignant B cells and the relatively low expression observed for A1 in the normal B cells prompted us to analyze A1 expression in plasma cells from 2 MM patients and 2 healthy subjects with increased amounts of starting mRNA (350 pg was increased to 400 pg) and an increase of 5 PCR cycles. When we did so, A1 expression was unexpectedly observed in both malignant and normal plasma cells (Figure 10B). However, the levels of A1 expression appear to be lower in the malignant plasma cells than in the normal plasma cells, suggesting possible repression by excessive Blimp-1 expression.
The occurrence of multiple aberrant mRNA expression levels and multiple genetic translocations is a common finding in analyses of gene expression in BM cells from MM patients. Such multiple perturbations in gene expression in complex pathways could be the result of mis-splicing of a single transcription factor into variant isoform(s), producing both normal and abnormal isoforms to variable levels. Our finding of a unique isoform of the Pax5 transcription factor in plasma cells of an MM patient prompted us to analyze Pax5 isoforms in healthy donors and MM patients. We concentrated our efforts on B-cell populations for 2 reasons: (1) Pax5 expression decreases at the plasma cell stage, and (2) our initial data revealed differences in the Pax5 profiles of healthy subjects and MM patients in B cells. We were able to determine the profile for Pax5 expression in healthy subjects although even healthy subjects occasionally exhibit a variable isoform. We identified multiple isoforms for Pax5 that were prevalent in MM patients and usually expressed in conjunction with decreased levels of the full-length Pax5 transcript. Unique forms of Pax5 have been previously encountered by others in mouse and human studies but were not fully characterized.24,31 The mechanisms(s) whereby Pax5 isoforms contribute to the disease phenotype is unclear. The altered isoforms could be replacing normal, functional Pax5 transcripts, thereby reducing the concentration of normal Pax5. It has been reported that Pax5 repressor and activator functions are independently dependent on Pax5 concentration: Pax5-specific DNA binding sites with positive regulatory activity have greater affinity for Pax 5 than those sites with negative regulatory activity.32 Thus, as expression levels of Pax5 decrease near the time of terminal differentiation, negative functions will be lost at higher concentrations than required for loss of positive functions. Alternatively, the unique isoforms are translated and are directly
responsible for misregulation downstream of Pax5. In vitro mutagenesis
and transient transfection experiments with a murine plasma cell line
have shown that the transactivating domain of Pax5 consists of an
activator domain that is negatively regulated by the adjacent sequences
at the C-terminus of the transactivating domain.23 If the
repressor region is deleted, the ability of Pax5 to activate
transcription can increase 8-fold.23 Dysfunctional Pax5
proteins apparently have considerable potential to disrupt normal cell
development due to the large number of Pax5-regulated genes.
Pax5-activated targets include CD19 and CD72 (costimulatory receptors),
the A prominent feature of the Pax5 profiles in B cells reported here is
the isoform missing exons 7-8 that is routinely seen in healthy
subjects. In contrast, it was detected in only 2 of 6 untreated MM
patients. However, the MM patients frequently had the isoform missing
exons 7-9. The loss of exons 7-9 is detected in the plasma cells of 2 of 4 healthy subjects; thus, a change to a 7-9-deleted isoform may be
part of a normal transition to the plasma cell state. If so, the
presence of the (7-9) Another prominent feature of both B cells and plasma cells is that most
exon deletions in MM patients occur within the 3'-end of Pax5. An
insert between exons 8 and 9 was observed in one MM patient. An exon
9-deleted isoform is missing most of the repressor module of Pax5 upon
translation and thus has the potential to mimic overexpression of Pax5.
Such overexpression of Pax5 has been implicated in other cancers,
including a subset of non-Hodgkin lymphomas, glioblastoma, and
medulloblastoma.37-39 A translated exon 8-deleted isoform
would be missing a portion of the activator region, which could explain
the low level of CD19 expression that is observed in some MM
patients.40 It is also notable that monoclonal IgE is only
rarely observed in myeloma, and Pax5 positively regulates the germ-line
transcription of the However, it has also been observed that expression of the mb-1 and LEF-1 genes are up-regulated by the paired domain polypeptide of Pax5 lacking any transactivation function.35 Thus, it is possible that all of the products that lack portions of the carboxy-terminus would retain some activating function. Interestingly, it has recently been reported that a frameshift mutation occurs in the transactivation domain of a Pax5 allele of the acute lymphoblastic leukemia cell line REH.23 This mutant transcript continues to translate, but not as Pax5 protein; thus, the carboxy-terminal end of Pax5 protein is also potentially disrupted in this tumor. We used sequence data in the human genome databases to probe the exon/intron boundary sequences of Pax5 and to determine intron sizes (Figure 2). We confirmed that all exon/intron boundaries of human Pax5 are homologous to those in mice. Pax5 is an uncommonly large gene of 198 349 base pairs; an average human gene is 27 kb.41 Most of the length of Pax5 is accounted for by 4 introns that are all more than 35 000 base pairs, and all of these lie downstream of exon 5 where we identified transactivating region deletions. Studies have shown that exon deletion frequency correlates directly with the sizes of the neighboring introns; thus, some endogenous exon loss might be expected for Pax5.42 It is also possible that aberrant splicing is causing the exon deletions in Pax5. Possible causes for aberrant splicing are point mutations at splice sites, gain or loss of long interspersed nuclear element-1's (LINE-1) in long introns such as are present in Pax5, or loss of proper mRNA surveillance.43-48 Also, it has been reported that elevated temperatures and low pH conditions, often found in tumor tissues, cause increases in alternative splicing.49 There are no obviously strong correlations between the Pax5 isoform profiles and the clinical data (Figure 6 and Table 1). It may be significant, however, that 2 patients (P13 and P17) with high PCLIs and 2 patients (P3 and P11) who exhibited poor response to treatment all have particularly pronounced disruptions of Pax5 expression. Some correlation between untreated and treated patients may exist, because the normal transcript that is missing exons 7-8 begins to reappear in some of the treated patients. It will be important to analyze same-patient Pax5 profiles throughout treatment to confirm this latter observation. We considered that there might be a relationship between aberrant Pax5 expression and the frequently observed up-regulation of interleukin-6 (IL-6) in MM. The partial homeodomain of Pax5 is an interaction motif for the retinoblastoma gene product (Rb), and it has been reported that the Rb gene product may be involved as a transcriptional repressor in modulating IL-6 gene expression during cellular differentiation and oncogenesis.50-51 Homozygous deletion of RB-1 has been identified in some MM patients and in the IL-6-autocrine human myeloma cell line U266.52 In future work it will be important to determine if the isoforms of Pax5 bind Rb protein, perhaps competing with the IL-6 gene promoter. The findings of the premature expression of Blimp-1, in conjunction with the potentially disrupted transactivating domains in Pax5 and the frequent low levels of full-length Pax5 expression, suggest that B-cell development in MM could be uncoupled from normal control by both of these transcription factors. Blimp-1 is believed to induce either Ig secretion and terminal differentiation in B cells or growth arrest and cell death, depending on the developmental stage of the cell, and it is up-regulated during the transition of mature B cells to Ig-secreting plasma cells.14,17 Blimp-1 also regulates several target genes, including transcription factor c-myc, antiapoptotic bcl-2 family member A1, syndecan-1, and J chain.30,53,54 We compared levels of full-length Pax5 expression in CD22+
and CD22 The findings of premature Blimp-1 expression in B cells from MM patients were also supported by our findings for expression of A1. A1 expression is normally repressed by Blimp-1, and we consistently observed the expected inverse correlation between Blimp-1 and A1 expression. We also investigated the expression levels of hXBP-1, another gene reportedly repressed by Pax5.35 In these experiments we did not find an apparent difference in levels of expression in the B cells between MM patients and healthy subjects (data not shown). It has recently been found that Blimp-1 expression in germinal centers is associated with a subset of cells with a phenotype intermediate between germinal center mature B cells and plasma cells and that these cells are nonapoptotic, proliferating cells.18 It is conceivable that malignant plasma cells could develop if proliferating B cells were pushed to differentiate prematurely. Other research indicates that Blimp-1 overexpression abrogates IL-4- and CD40-mediated suppression of terminal B-cell differentiation but arrests isotype switching.55 The expression of Blimp-1 in B cells of MM patients may contribute to that paradox observed in MM: loss of polyclonality accompanied by proliferation of a monoclonal cell type. We propose that the coupling of premature Blimp-1 expression with alterations and deficits in Pax5 expression may cause some proliferating B cells to prematurely progress to a "plasma cell-like" state while bypassing isotype switching events and control of proliferation.
Submitted November 9, 2001; accepted August 26, 2002.
Supported in part by grant 2A2887, International Myeloma Foundation, North Hollywood, CA; grant Mayo-1: B-Cell; and grant CA62242, Studies of Monoclonal Gammopathies, Cancer Center; both of the Mayo Clinic, Rochester, MN.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Nancy D. Borson, Rm 5-42A, Guggenheim Bldg, Mayo Clinic, 200 1st St SW, Rochester, MN 55905; e-mail: borson.nancy{at}mayo.edu.
1. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58[CrossRef][Medline] [Order article via Infotrieve]. 2. Reichardt V, Okada C, Benike C, et al. Idiotypic vaccination using dendritic cells for multiple myeloma patients after autologous peripheral blood stem cell transplantation [abstract]. Blood. 1996;10(suppl):481a. 3. Kwal LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet. 1995;345:1016-1020[CrossRef][Medline] [Order article via Infotrieve]. 4. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors [see comments]. N Engl J Med. 1992;327:1209-1215[Abstract]. 5. Bogen B. Peripheral T cell tolerance as a tumor escape mechanism: depletion of CD4 T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol. 1996;26:2671-2679[Medline] [Order article via Infotrieve]. 6. Bogen B, Munthe L, Sollien A, et al. Naive CD4 T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol. 1995;25:3079-3086[Medline] [Order article via Infotrieve].
7.
Yi Q, Osterborg A, Bergenbrant S, et al.
Idiotype-reactive T-cell subsets and tumor load in monoclonal gammapothies.
Blood.
1995;86:3043-3049 8. Osterborg A, Yi Q, Bergenbrandt S. Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. Br J Haematol. 1995;89:110-116[Medline] [Order article via Infotrieve]. 9. Cull G, Durrant L, Stainer C, Haynes A, Russell N. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol. 1999;107:648-655[CrossRef][Medline] [Order article via Infotrieve].
10.
Reichardt VL, Okada CY, Liso A, et al.
Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma 11. McClelland M, Welsh J. RNA fingerprinting by arbitrarily primed PCR. PCR Methods Appl. 1994;4:S66-S81[Medline] [Order article via Infotrieve]. 12. Hagman J, Wheat W, Fitzsimmons D, Hodsdon W, Negri J, Dizon F. Pax-5/BSAP: regulator of specific gene expression and differentiation in B lymphocytes. Curr Top Microbiol Immunol. 2000;245:169-194[Medline] [Order article via Infotrieve].
13.
Zwollo P, Arrieta H, Ede K, Molinder K, Desiderio S, Pollock R.
The Pax-5 gene is alternatively spliced during B-cell development.
J Biol Chem.
1997;272:10160-10168 14. Usui T, Wakatsuki Y, Matsunaga Y, Kaneko S, Kosek H, Kita T. Overexpression of B cell-specific activator protein (BSAP/Pax-5) in a late B cell is sufficient to suppress differentiation to an Ig high producer cell with plasma cell phenotype. J Immunol. 1997;158:3197-3204[Abstract]. 15. Nagy M, Chapuis B, Matthes T. Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells. Br J Haematol. 2002;116:429-435[CrossRef][Medline] [Order article via Infotrieve].
16.
Lin K, Angelin-Duclos C, Kuo T, Calame K.
Blimp-1 dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells.
Mol Cell Biol.
2002;22:4771-4780
17.
Soro PG, Morales AP, Martinez MJA, et al.
Differential involvement of the transcription factor Blimp-1 in T cell-independent and -dependent B cell differentiation to plasma cells.
J Immunol.
1999;163:611-617
18.
Angelin-Duclos C, Cattoretti G, Lin KI, Calame K.
Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo.
J Immunol.
2000;165:5462-5454
19.
McClelland M, Ralph D, Cheng R, Welsh J.
Interactions among regulators of RNA abundance characterized using RNA fingerprinting by arbitrarily primed PCR.
Nucleic Acids Res.
1994;22:4419-4431
20.
Bauer D, Muller H, Reich J, et al.
Identification of differentially expressed mRNA species by an improved display technique (DDRT-PCR).
Nucleic Acids Res.
1993;21:4272-4280 21. Borson ND, Strausbauch MA, Wettstein PJ, Oda RP, Johnston SL, Landers JP. Direct quantitation of RNA transcripts by competitive single-tube RT-PCR and capillary electrophoresis. Biotechniques. 1998;25:130-137[Medline] [Order article via Infotrieve]. 22. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215:403-410[CrossRef][Medline] [Order article via Infotrieve]. 23. Dorfler P, Busslinger M. C-terminal activating and inhibitory domains determine the transactivation potential of BSAP (Pax-5), Pax-2 and Pax-8. EMBO J. 1996;15:1971-1982[Medline] [Order article via Infotrieve]. 24. Kaneko H, Ariyasu T, Inoue R, et al. Expression of Pax5 gene in human haematopoietic cells and tissues: comparison with immunodeficient donors. Clin Exp Immunol. 1998;111:339-344[CrossRef][Medline] [Order article via Infotrieve].
25.
Barberis A, Widenhorn K, Vitelli L, Busslinger M.
A novel B-cell lineage-specific transcription factor present at early but not late stages of differentiation.
Genes Dev.
1990;4:849-859
26.
Adams B, Dorfler P, Aguzzi A, et al.
Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis.
Genes Dev.
1992;6:1589-1607
27.
Nomura N, Miyajima N, Sazuka T, et al.
Prediction of the coding sequences of unidentified human genes.
DNA Res.
1994;1:47-56 28. Bouchard M, Pfeffer P, Busslinger M. Functional equivalence of the transcription factors Pax2 and Pax5 in mouse development. Development. 2000;127:3703-3713[Abstract]. 29. Kozmik Z, Holland ND, Kalousova A, et al. Characterization of an amphioxus paired box gene, AmphiPax2/5/8: developmental expression patterns in optic support cells, nephridium, thyroid-like structures and pharyngeal gill sits, but not in the midbrain-hindbrain boundary region. Development. 1999;126:1295-1304[Abstract]. 30. Knodel M, Kuss AW, Lindemann D, Berberich I, Schimpl A. Reversal of Blimp-1-mediated apoptosis by A1, a member of the Bcl-2 family. Eur J Immunol. 1999;29:2988-2998[CrossRef][Medline] [Order article via Infotrieve].
31.
Zwollo P, Arrieta H, Ede K, Molinder K, Desiderio S, Pollock R.
The Pax-5 gene is alternatively spliced during B-cell development.
J Biol Chem.
1997;272:10160-10168
32.
Wallin JJ, Gackstetter ER, Koshland ME.
Dependence of BSAP repressor and activator functions on BSAP concentration.
Science.
1998;279:1961-1964 33. Gisler R, Akerblad P, Sigvardsson M. A human early B-cell factor-like protein participates in the regulation of the human CD19 promoter. Mol Immunol. 1999;36:1067-1077[CrossRef][Medline] [Order article via Infotrieve]. 34. Liao F, Birshtein BK, Busslinger M, Rothman P. The transcription factor BSAP (NF-HB) is essential for immunoglobulin germ-line epsilon transcription. J Immunol. 1994;152:2904-2911[Abstract]. 35. Nutt SL, Morrison AM, Dorfler P, Rolink A, Busslinger M. Identification of BSAP (PAX-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J. 2000;17:2319-2333. 36. Stuart ET, Haffner R, Oren M, Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J. 1995;14:5638-5645[Medline] [Order article via Infotrieve]. 37. Hamada T, Yonetani N, Ueda C, et al. Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9:14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma. Br J Haematol. 1998;102:691-700[CrossRef][Medline] [Order article via Infotrieve]. 38. Stuart ET, Kioussi C, Aguzzi A, Gruss P. PAX5 expression correlates with increasing malignancy in human astrocytomas. Clin Cancer Res. 1995;1:207-214[Abstract].
39.
Kozmik A, Sure U, Ruedi D, Busslinger M.
Deregulated expression of PAX5 in medulloblastoma.
Proc Natl Acad Sci U S A.
1995;92:5709-5713 40. Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97:46-55[CrossRef][Medline] [Order article via Infotrieve]. 41. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921[CrossRef][Medline] [Order article via Infotrieve].
42.
Bell MV, Cowper AE, Lefranc MP, Bell JI, Screaton GR.
Influence of intron length on alternative splicing of CD44.
Mol Cell Biol.
1998;18:5930-5941 43. Chabot B. Directing alternative splicing: cast and scenarios. Trends Genet. 1996;12:472-478[CrossRef][Medline] [Order article via Infotrieve]. 44. Lopez AJ. Alternative splicing of PRE-mRNA: developmental consequences and mechanisms of regulation. Annu Rev Genet. 1998;32:279-305[CrossRef][Medline] [Order article via Infotrieve]. 45. McNaughton JC, Hughes G, Jones WA, Stockwell PA, Klamut HJ, Petersen GB. The evolution of an intron: analysis of a long, deletion-prone intron in the human dystrophin gene. Genomics. 1997;40:294-304[CrossRef][Medline] [Order article via Infotrieve]. 46. Li L, Ohman T, Deeb S, Fukuchi K. Analysis of mouse intron 7 DNA sequence of the APP gene: comparison with the human homologue. DNA Seq. 2000;10:219-228. 47. Rohlfs EM, Puget N, Graham ML, et al. An alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chromosomes Cancer. 2000;28:300-307[CrossRef][Medline] [Order article via Infotrieve]. 48. Morgan NV, Tipping AJ, Joenje H, Mathew CG. High frequency of large intragenic deletions in the Fanconi anemia group A gene. Am J Hum Genet. 1999;65:1330-1341[CrossRef][Medline] [Order article via Infotrieve].
49.
Kaufmann D, Leistner W, Kruse P, et al.
Aberrant splicing in several human tumors in the tumor suppressor genes neurofibromatosis type 1, neurofibromatosis type 2, and tuberous sclerosis 2.
Cancer Res.
2002;62:1503-1509 50. Eberhard D, Busslinger M. The partial homeodomain of the transcription factor Pax-5 (BSAP) is an interaction motif for the retinoblastoma and TATA-binding proteins. Cancer Res. 1999;59:1716-1725.
51.
Santhanam U, Ray A, Sehgal PB.
Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product.
Proc Natl Acad Sci U S A.
1991;88:7605-7609 52. Juge-Morineau N, Harousseau JL, Amiot M, Bataille R. The retinoblastoma susceptibility gene RB-1 in multiple myeloma. Leuk Lymphoma. 1997;24:229-237[Medline] [Order article via Infotrieve].
53.
Lin Y, Wong K, Calame K.
Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation.
Science.
1997;276:596-599
54.
Messika EJ, Lu PS, Sung YJ, et al.
Differential effect of B lymphocyte-induced maturation protein (Blimp-1) expression on cell fate during B cell development.
J Exp Med.
1998;188:515-525 55. Knodel M, Kuss AW, Berberich I, Schimpl A. Blimp-1 overexpression abrogates IL-4- and CD40-mediated suppression of terminal B cell differentiation but arrests isotype switching. Eur J Immunol. 2001;31:1972-1980[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  F. Mora-Lopez, E. Reales, J. A. Brieva, and A. Campos-Caro Human BSAP and BLIMP1 conform an autoregulatory feedback loop Blood, November 1, 2007; 110(9): 3150 - 3157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L.M. Boylan, M. A. Gosse, S. E. Staggs, S. Janz, S. Grindle, G. S. Kansas, and B. G. Van Ness A Transgenic Mouse Model of Plasma Cell Malignancy Shows Phenotypic, Cytogenetic, and Gene Expression Heterogeneity Similar to Human Multiple Myeloma Cancer Res., May 1, 2007; 67(9): 4069 - 4078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lotz, S. A. Mutallib, N. Oehlrich, U. Liewer, E. A. Ferreira, M. Moos, M. Hundemer, S. Schneider, S. Strand, C. Huber, et al. Targeting Positive Regulatory Domain I-Binding Factor 1 and X Box-Binding Protein 1 Transcription Factors by Multiple Myeloma-Reactive CTL J. Immunol., July 15, 2005; 175(2): 1301 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Oppezzo, G. Dumas, A. I. Lalanne, B. Payelle-Brogard, C. Magnac, O. Pritsch, G. Dighiero, and F. Vuillier Different isoforms of BSAP regulate expression of AID in normal and chronic lymphocytic leukemia B cells Blood, March 15, 2005; 105(6): 2495 - 2503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Robichaud, M. Nardini, M. Laflamme, M. Cuperlovic-Culf, and R. J. Ouellette Human Pax-5 C-terminal Isoforms Possess Distinct Transactivation Properties and Are Differentially Modulated in Normal and Malignant B Cells J. Biol. Chem., November 26, 2004; 279(48): 49956 - 49963. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
) isoform increases to 57% in treated B-cell populations. The
isoform missing exons 7, 8, and 9 in tandem was found in 67% and 43%
of the B-cell populations of untreated and treated MM patients,
respectively; this isoform was not found in normal B cells. It was,
however, found in the plasma cells of 2 of 4 healthy subjects. An
isoform with an insert of 83 nucleotides between exons 8 and 9 was
detected in the plasma cells of P17. In general, multiple isoforms were expressed in MM patients compared with healthy subjects, particularly in treated MM patients, and the deletions occurred primarily in the
3'-end of Pax5.
gene (I
2
promoter) and
2 enhancer regions (the Ig heavy chain 3' C
3'
enhancer).
a feasibility study.
Blood.
1999;93:2411-2419